Latham & Watkins Advises on Altaris Acquisition of Simulations Plus for Approximately US$375 Million

Simulations Plus, Inc. (Nasdaq: SLP) (Simulations Plus or the Company), a global leader in model‑informed and AI‑accelerated drug development that advances biopharma innovation, has announced that it has entered into a definitive agreement to be acquired by affiliates of Altaris, LLC (Altaris), an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry, in an all‑cash transaction. At or about the closing of the transaction, Altaris anticipates the Company will be combined with Chemical Computing Group (CCG), an existing Altaris portfolio company that provides advanced molecular design software to customers across the pharmaceutical, chemical, and materials sectors.

Latham & Watkins LLP represented Truist Securities, Inc. as financial advisor to Altaris in the transaction with a team led by Stelios Saffos, Global Chair of Latham’s Capital Markets and Hybrid Capital practices, and partner John Lister, with associates Rob Rogowski, Samantha Rudd, and Judy Lee. Advice was also provided on tax matters by partner Bora Bozkurt, with associate Shiyi Parsons; on UK finance matters by partner Fergus Wheeler, with associate Marco Zacchino.